-
Extended interval dosing of ocrelizumab modifies the repopulation of B cells without altering the clinical efficacy in multiple sclerosis
Rodriguez-Mogeda, C., van Lierop, Z. Y. G. J., van der Pol, S. M. A., Coenen, L., Hogenboom, L., Kamermans, A., Rodriguez, E., van Horssen, J., van Kempen, Z. L. E., Uitdehaag, B. M. J., Teunissen, C. E., Witte, M. E., Killestein, J. & de Vries, H. E., Dec 2023, In: Journal of neuroinflammation. 20, 1, p. 215 215.Research output: Contribution to journal › Article › Academic › peer-review
-
Prospective trial of natalizumab personalised extended interval dosing by therapeutic drug monitoring in relapsing-remitting multiple sclerosis (NEXT-MS)
Toorop, A. A., van Lierop, Z. Y., Gelissen, L. M., Hoitsma, E., Zeinstra, E. M., van Rooij, L. C., van Munster, C. E., Vennegoor, A., Mostert, J. P., Wokke, B. H., Kalkers, N. F., Hoogervorst, E. L., van Eijk, J. J., Roosendaal, C. M., Kragt, J. J., Eurelings, M., van Genugten, J., Nielsen, J., Sinnige, L., Kloosterziel, M. E., & 16 others, 14 Nov 2023, (E-pub ahead of print) In: Journal of neurology, neurosurgery, and psychiatry.Research output: Contribution to journal › Article › Academic
-
Smartphone-derived keystroke dynamics are sensitive to relevant changes in multiple sclerosis
Lam, K-H., Twose, J., McConchie, H., Licitra, G., Meijer, K., de Ruiter, L., van Lierop, Z., Moraal, B., Barkhof, F., Uitdehaag, B., de Groot, V. & Killestein, J., Feb 2022, In: European journal of neurology. 29, 2, p. 522-534 13 p.Research output: Contribution to journal › Article › Academic › peer-review
- All publications
